Conscio Group’s Post

Nerviplex Clinical Trial

🔥🔥🔥 Exciting News: This Friday, October 25th, in Boston! Join us for the "2024 AHEA NewCo Breakthrough: Pioneering the Future of Bispecific Antibodies" Roadshow at The University of Massachusetts Boston, from 1-7 PM (EST). Co-hosted by the American Healthcare Executive Association (AHEA), IntelliPro Group (IPG), InScienceWeTrust BioAdvisory (ISWTB), and InScienceWeTrust Community (ISWTC), this half-day event will spotlight the most cutting-edge projects in the bispecific antibodies sector. It's a must-attend opportunity for investors, biopharma innovators, and emerging biotech teams to connect, collaborate, and discover new ventures! The event will feature a panel discussion led by Weiyong Sun, CBO of Jiangsu Hanosh, and Leon 'Jun' T., Founding Partner of InScienceWeTrust BioAdvisory (ISWTB) & InScienceWeTrust Community (ISWTC). Selected companies will present exciting assets and data in the bispecific antibodies space. 📢 Seats are limited! Don’t miss your chance—scan the QR code on the poster or register via the link below before space runs out: https://lnkd.in/gBNUUSRH 🔒 See you there! 🤩 #BispecificAntibodies #Biopharma #BostonEvents #HealthcareInnovation #BiotechInvestment #NewCo #AHEA #IntelliPro #ISWTBioAdvisory #BiotechBreakthroughs #LifeSciences #Healthcare

#CPhI and #BSA24 are now done & the vibe was just great. ⏭️ - and already preparing for the Festival of Biologics. There are really good talks about #mabs and #biosimilars, where I'm much curious to listen & also very interesting people to meet. #tentamus #velalabs #labsforlife #conference #networking #FoB24

BIOSHARES has penned an insightful article about AdAlta’s strategy to commercialise its suite of singe domain antibodies (i-bodies). The article highlights the important role two special purpose vehicles are playing in delivering this strategy. The first is AdSolis, which houses lead drug candidate AD-214 which is heading towards Phase II clinical trials. The second is the AdCella subsidiary executing an 'East to West Reverse Innovation Strategy & Business Model’ for cellular immunotherapies, harnessing Asia innovation, Australian capabilities and with AdAlta's i-body® platform.

The wait is over, SCOPE 2024 is finally here! Segmed is thrilled to be attending the SCOPE Europe Summit tomorrow in Barcelona. We are excited to explore the latest trends in clinical trial innovation, planning, and operations at SCOPE Europe 2024. The conference offers a fantastic opportunity to learn from new case studies and network with industry leaders from pharma, Biotech, and clinical research organizations. Our curated, fit-for-purpose regulatory grade datasets and multimodal longitudinal datasets can transform and help optimize clinical trials. Let’s connect to discuss how real-world imaging datasets (RWiD) can enhance clinical trials through improved patient selection and data-driven insights. Our Chief Strategy Officer, Kristin Yakimow will be there at the #SCOPE summit. Join us to learn more about Segmed and how we can collaborate- https://hubs.li/Q02VxrFf0 Looking forward to productive conversations! #SCOPE2024 #ClinicalTrials #RWiD #Innovation #Pharma #Biotech #CRO #DrugDevelopment #Segmed #RWD #imagingdata #realworldimagingdata

📢 #breakingnews! We will exhibit at #CPHI2024 in #Milano, from 8 to 10 October: visit us at stand #6D52. 🔗 Click to read the full news and #register for #free. Our colleagues look forward to seeing you in Milano! Maria Teresa Legrottaglie Giacomo Congiu Sergio Bizzarri Martina Mastropasqua Luca Montroni Guido Rovati Fabiana Durante Valentina Putzu DELTAPHARMA - part of Faravelli Group #faravellipharmadivision #greatsatisfaction #APIs #greatrawmaterials #excipients #behindgreatsatisfactionarealwaysgreatrawmaterials

“Under the agreement, Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009. The two parties will jointly focus on the early-stage development of this ADC candidate, after which Roche will take over full development. Innovent will receive an upfront payment of US$80 million and is eligible to receive up to US$1 billion in development and commercial milestone payments, along with tiered royalties on net sales.” I guess the first of the year, keeping up with the pace set in 2024! One would expect more announcements in the lead up to JPM What new trends will we see in 2025 on the China to global flow? A continuation of 24, or new trends? Let me know your thoughts in the comments #china #biotech #innovation

🌟 Exciting News! 🌟 We are thrilled to share that our CEO & Co-Founder, LakshmiDevi Ethirajan, will be moderating a panel at the 20th BioPharma Nexus Conference in San Diego. The panel discussion will focus on "Advancing Hit Discovery for Complex and Emerging Targets. Join us in San Diego on May 8-9 to gain insights from industry leaders and see how innovations are shaping the future of #DrugDiscovery!

Excited to kick off 2025 with a strong presence at key healthcare conferences in the U.S.! Join me and our Chairman, Mark Germain, as we connect with industry leaders to drive innovation in immunotherapeutics and biologics. Looking forward to collaborating with investors, pharma partners, and prospective clients. Let's make this year impactful! #VHH #MaxPlanck #Immunotherapy #Biologics #CDMO #Biotech #InvestmentOpportunities #HealthcareConferences #antibodies #Immunology #inflammation #psoriasis

Let’s connect